Executive Summary

Innovation and investment in next generation medicines and therapies have never been more important or appreciated than they are today. As the world grapples with COVID-19, we have witnessed unprecedented cooperation between public and private enterprises in the fight against coronavirus. Developments in the race for a vaccine and therapeutics to treat, and hopefully, eradicate COVID-19 are happening at breakneck speed – all while most of us are working from home and settling into a “new normal”.

In recent days, the Stifel Healthcare Group surveyed dozens of top life sciences industry executives and investors to better understand sentiment toward treatment development and distribution, as well as the anticipated effect on business post-COVID.

Key survey findings include:

- There’s uniform optimism that a COVID-19 vaccine will be developed, distributed, and made available to all but probably not until late next year or beyond.
- Almost all respondents are expecting a “second wave” of COVID-19 and half fear it will be serious enough to warrant more closures and restrictions.
- An overwhelming majority expect another pandemic this decade.
- A significant majority believe the COVID-19 experience will change the way the FDA and companies work together in the future.
- Even once people are allowed back into the workplace, many are planning to make lasting changes to their routines, including more telecommuting and less business travel.

(1) The survey was conducted from June 10, 2020, through June 18, 2020, and included 50 executive and investor respondents.
When do you expect the first vaccine for COVID-19 will be approved?

- **Late 2020**: 16%
- **Q1 2021**: 40%
- **Late 2021**: 34%
- **2022 or later**: 8%
- **Not expecting a vaccine**: 2%
When will a vaccine for COVID-19 be available for all in the US?

- 22% expect a vaccine in Q1 2021
- 40% expect a vaccine in late 2021
- 36% expect a vaccine in 2022 or later
- 2% do not expect a vaccine
Where will the first COVID-19 vaccine be developed?

- United States: 80%
- China: 12%
- Somewhere else: 8%
When do you expect the next therapeutic (after Remdesivir) for COVID-19 be approved for use?

- 38% expect it in Q3 or Q4 2020
- 20% expect it in Q1 2021
- 38% expect it in Q2 2021 or later
- 4% do not expect additional therapeutics
When do you expect to stop working from home exclusively?

- 34% expect to stop working from home exclusively by Q3 2020.
- 14% expect to stop by Q4 2020.
- 20% expect to stop by Q1 2021.
- 12% expect to stop by Q2 2021 or later.
- 14% intend to continue working from home exclusively.
- 6% are not currently working exclusively from home.
Once allowed back into the office full-time, will you change your work habits and work remotely more frequently than before COVID-19?

- Yes significantly: 48%
- Yes somewhat: 36%
- No: 14%
- Not applicable: 2%
When do you expect to regularly travel again for business?

- Q3 2020: 8%
- Q4 2020: 20%
- Q1 2021: 38%
- Q2 2021 or later: 32%
- I am planning to eliminate business travel: 2%
Do you expect a potential “second wave” of infections will lead to significant additional closures/restrictions that are now being lifted prior to a broadly available vaccine or herd immunity?
Do you think COVID-19 will change the way the FDA and companies work together in the future?

- Yes significantly: 26%
- Yes somewhat: 62%
- No: 12%
Will investor enthusiasm for vaccine and infectious disease companies continue post COVID-19?

- Yes: 56%
- No: 44%
Will governments continue to invest in pandemic/disease preparedness post COVID-19?

90% Yes
10% No
When do you think the next pandemic (after COVID-19) will happen?

- Less than 5 years: 40%
- 5-10 years: 44%
- Not for a long time: 16%
Will drug pricing be an issue in the November presidential election this year?

- Yes significantly: 10%
- Yes but in passing: 66%
- No: 24%
Will President Trump be re-elected?

- Yes: 40%
- No: 60%
Stifel collectively refers to Stifel, Nicolaus & Company, Incorporated, a broker-dealer registered with the United States Securities and Exchange Commission ("SEC") and member of the Financial Industry National Regulatory Authority ("FINRA") and other affiliated broker-dealer subsidiaries of Stifel Financial Corp. The information and statistical data contained herein have been obtained from sources that Stifel believes are reliable, but Stifel makes no representation or warranty as to the accuracy or completeness of any such information or data and expressly disclaims any and all liability relating to or resulting from your use of these materials. The information and data contained herein are current only as of the date(s) indicated, and Stifel has no intention, obligation, or duty to update these materials after such date(s). These materials are for informational purposes only do not constitute an offer to sell or the solicitation of an offer to buy any securities, and Stifel is not soliciting any action based on this material. This material was prepared by Stifel Investment Banking and is not the product of the Stifel Research Department. It is not a research report, and should not be construed as such. This material may not be reproduced, re-distributed or passed to any other person or published in whole or in part for any purpose without the prior consent of Stifel. © 2020 Stifel.